全文获取类型
收费全文 | 2995篇 |
免费 | 147篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 131篇 |
妇产科学 | 75篇 |
基础医学 | 402篇 |
口腔科学 | 34篇 |
临床医学 | 253篇 |
内科学 | 747篇 |
皮肤病学 | 71篇 |
神经病学 | 252篇 |
特种医学 | 56篇 |
外科学 | 373篇 |
综合类 | 7篇 |
一般理论 | 1篇 |
预防医学 | 108篇 |
眼科学 | 63篇 |
药学 | 169篇 |
中国医学 | 9篇 |
肿瘤学 | 396篇 |
出版年
2023年 | 17篇 |
2022年 | 16篇 |
2021年 | 51篇 |
2020年 | 46篇 |
2019年 | 56篇 |
2018年 | 76篇 |
2017年 | 54篇 |
2016年 | 50篇 |
2015年 | 79篇 |
2014年 | 114篇 |
2013年 | 106篇 |
2012年 | 187篇 |
2011年 | 201篇 |
2010年 | 133篇 |
2009年 | 124篇 |
2008年 | 203篇 |
2007年 | 206篇 |
2006年 | 200篇 |
2005年 | 196篇 |
2004年 | 202篇 |
2003年 | 182篇 |
2002年 | 173篇 |
2001年 | 54篇 |
2000年 | 27篇 |
1999年 | 35篇 |
1998年 | 28篇 |
1997年 | 28篇 |
1996年 | 31篇 |
1995年 | 30篇 |
1994年 | 20篇 |
1993年 | 16篇 |
1992年 | 22篇 |
1991年 | 19篇 |
1990年 | 20篇 |
1989年 | 22篇 |
1988年 | 17篇 |
1987年 | 15篇 |
1986年 | 6篇 |
1985年 | 10篇 |
1984年 | 12篇 |
1983年 | 5篇 |
1982年 | 13篇 |
1980年 | 10篇 |
1979年 | 10篇 |
1978年 | 7篇 |
1977年 | 5篇 |
1976年 | 3篇 |
1975年 | 6篇 |
1973年 | 2篇 |
1962年 | 1篇 |
排序方式: 共有3152条查询结果,搜索用时 21 毫秒
1.
Andrea Ferrari MD Daniel Orbach MD Michela Casanova MD Max M. van Noesel MD Pablo Berlanga MD Bernadette Brennan MD Nadege Corradini MD Reineke A. Schoot MD Gema L. Ramirez-Villar MD Lisa Lyngsie Hjalgrim MD Rita Alaggio MD Gabriela Guillen Burrieza MD Akmal Safwat MD Alison L. Cameron MD Rick R. van Rijn MD Veronique Minard-Colin MD Ilaria Zanetti BSc Gianni Bisogno MD Julia C. Chisholm MD Johannes H. M. Merks MD 《Cancer》2023,129(16):2542-2552
Background
Limited data exist on the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined.Methods
This cohort study reports on pediatric adult-type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single-arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group. Treatment programs were originally designed for patients with metastatic rhabdomyosarcoma, i.e., nine courses of multidrug chemotherapy (with or without bevacizumab in the BERNIE study), followed by 12 cycles of maintenance therapy, whereas radiotherapy and/or surgery (on primary tumor and/or metastases) were delayed until after seven courses of chemotherapy had been administered.Results
The study included 61 patients <21 years old treated from July 2008 to December 2016. The lung was the site of metastases in 75% of the cases. All patients received multi-agent chemotherapy, 44% had local therapy to primary tumor, and 18% had treatment of metastases. Median time to progression/relapse was 6 months. A high rate of tumor progression was observed during the initial part of the chemotherapy program. With a median follow-up of 41.5 months (range, 2–111 months), 3-year event-free survival and overall survival were 15.4% (95% confidence interval [CI], 7.6–25.7) and 34.9% (95% CI, 22.7–47.5), respectively. There were no statistically significant differences in outcome depending on the type of treatment administered.Conclusions
The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge.Plain Language Summary
- Pediatric non-rhabdomyosarcoma soft tissue sarcomas form a heterogeneous group of rare tumors.
- Although recent international studies have defined the standard of care for patients with localized disease, limited data are available on the clinical behavior of patients with distant metastases.
- This study on 61 metastatic cases treated on two prospective European protocols confirms that the chances of survival of such patients are often dismal and a standard treatment is still lacking.
2.
Simonetta Viviani Arabella Mazzocchi Chiara Pavoni Francesca Taverna Andrea Rossi Caterina Patti Alessandra Romano Livio Trentin Roberto Sorasio Anna Guidetti Daniela Gottardi Corrado Tarella Michele Cimminiello Roberta Zanotti Lucia Farina Andrés José Maria Ferreri Marina Galbiati Paolo Corradini Alessandro Massimo Gianni Andrea Gallamini Alessandro Rambaldi 《Hematological oncology》2020,38(4):501-508
Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation-regulated chemokine (TARC) levels, to improve risk assessment in patients treated according to HD0607 PET-driven trial (#NCT00795613). In 266 patients with available serum samples, who have agreed to participate in a sub-study for assessment of the role of TARC monitoring, serum TARC levels were measured at baseline and at time of PET-2 by commercially available ELISA test kits. The primary end-point was to evaluate the association between TARC after 2 ABVD cycles and PFS. Median TARC-2 values were significantly higher in PET-2-positive patients compared to PET-2-negative patients (P = .001), and in patients with treatment failure compared to those in continuous CR (P = .01). The 4-year PFS significantly differed between patients with TARC-2 >800 pg/mL vs ≤800 pg/mL (64% vs 86%, P = .0001). Moreover, among PET-2-negative patients, elevated TARC-2 identified those with a worse prognosis (74% vs 89%; P = .01). In multivariable analysis, TARC-2 >800 pg/mL was a significant independent predictor of PFS in the whole study population (HR 2.39, P = .004) and among the PET-2-negative patients (HR 2.49, P = .02). In conclusion, our results indicate that TARC-2 serum levels above 800 pg/mL suggest the need for a stringent follow-up in PET-2-negative patients, and the evaluation of new drugs in PET-2-positive, who will likely fail to respond to intensification with escalated BEACOPP. 相似文献
3.
4.
Haya Mohammed BSc MChB M. Yousuf Salmasi MRCS Massimo Caputo PhD Gianni D. Angelini PhD Hunaid A. Vohra PhD 《Journal of cardiac surgery》2020,35(6):1209-1219
Background
Limited data exists demonstrating the efficacy of minimally invasive surgery (MIS) compared to median sternotomy (MS) for multiple valvular disease (MVD). This systematic review and meta-analysis aims to compare operative and peri-operative outcomes of MIS vs MS in MVD.Methods
PubMed, Ovid, and Embase were searched from inception until August 2019 for randomized and observational studies comparing MIS and MS in patients with MVD. Clinical outcomes of intra- and postoperative times, reoperation for bleeding and surgical site infection were evaluated.Results
Five observational studies comparing 340 MIS vs 414 MS patients were eligible for qualitative and quantitative review. The quality of evidence assessed using the Newcastle-Ottawa scale was good for all included studies. Meta-analysis demonstrated increased cardiopulmonary bypass time for MIS patients (weighted mean difference [WMD], 0.487; 95% confidence interval [CI], 0.365-0.608; P < .0001). Similarly, aortic cross-clamp time was longer in patients undergoing MIS (WMD, 0.632; 95% CI, 0.509-0.755; P < .0001). No differences were found in operative mortality, reoperation for bleeding, surgical site infection, or hospital stay.Conclusions
MIS for MVD have similar short-term outcomes compared to MS. This adds value to the use of minimally invasive methods for multivalvular surgery, despite conferring longer operative times. However, the paucity in literature and learning curve associated with MIS warrants further evidence, ideally randomized control trials, to support these findings.5.
Canadian Journal of Anesthesia/Journal canadien d'anesthésie - 相似文献
6.
7.
de la Pena-Almaguer Erasmo Hautemann David Pedrizzetti Gianni 《The international journal of cardiovascular imaging》2021,37(12):3589-3590
The International Journal of Cardiovascular Imaging - 相似文献
8.
Lunetta Christian Moglia Cristina Lizio Andrea Caponnetto Claudia Dubbioso Raffaele Giannini Fabio Matà Sabrina Mazzini Letizia Sabatelli Mario Siciliano Gabriele Simone Isabella Laura Sorarù Gianni Toriello Antonella Trojsi Francesca Vedovello Marcella D’Ovidio Fabrizio Filippi Massimo Calvo Andrea 《Journal of neurology》2020,267(11):3258-3267
Journal of Neurology - The aim of the study is to analyze the ALS disease progression and respiratory function of Italian patients treated with edaravone (EVN), as well as the adherence to, and the... 相似文献
9.